内分泌科

订阅

MedSci主页 / 所有栏目 / 内分泌科

Diabetes Care：小心中央肥胖会带给你2型糖尿病的风险

2015-04-13 崔倩 MedSci原创

2型糖尿病肥胖
关注

目的：腹部肥胖是2型糖尿病（T2D）的主要危险因素。我们的目的是研究遗传易感性向心性肥胖之间的关联，通过腰围与臀围的比例（WHR）基因分和T2D风险进行评估。 研究设计和方法：目前的研究包括2591名2型糖尿病患者和3052名无2型糖尿病参与者，这些参与者均为欧洲血统来自于护士健康研究的（NHS）和卫生专业人员随访研究（HPFS）。使用基于14位点建立了WHR遗传得分估计遗传倾向向心性肥胖。

目的：腹部肥胖是2型糖尿病（T2D）的主要危险因素。我们的目的是研究遗传易感性向心性肥胖之间的关联，通过腰围与臀围的比例（WHR）基因分和T2D风险进行评估。

研究设计和方法：目前的研究包括2591名2型糖尿病患者和3052名无2型糖尿病参与者，这些参与者均为欧洲血统来自于护士健康研究的（NHS）和卫生专业人员随访研究（HPFS）。使用基于14位点建立了WHR遗传得分估计遗传倾向向心性肥胖。

结果：我们发现，中心性肥胖的遗传得分与高T2D风险是线性相关的。NHS（女性）和HPFS（男性）的结果类似。在合并的结果中，每个中心性肥胖遗传得分的点与发展T2D的1.04比值（OR）相关联（95％Cl，1.01-1.07），而当与多元调整后极端分位数遗传得分比较时OR为1.24（1.03-1.45）。

结论：数据表明，遗传易感性中心性肥胖与较高的2型糖尿病风险相关。该关联是由中央肥胖介导的。

原始出处

Huang T1, Qi Q2, Zheng Y1, Ley SH1, Manson JE3, Hu FB4, Qi L5.Genetic Predisposition to Central Obesity and Risk of Type 2 Diabetes: Two Independent Cohort Studies.Diabetes Care. 2015 Apr 7.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1901276, encodeId=cbf119012e6ed, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Oct 13 20:42:00 CST 2015, time=2015-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759536, encodeId=c71f1e59536db, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Jan 24 20:42:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637067, encodeId=502c163e06752, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jun 22 01:42:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27076, encodeId=4a812e076e4, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:38:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22752, encodeId=753a22e5279, content=有意思！, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Wed May 06 14:35:00 CST 2015, time=2015-05-06, status=1, ipAttribution=)]
    2015-10-13 木头人513

    #Diabetes#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1901276, encodeId=cbf119012e6ed, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Oct 13 20:42:00 CST 2015, time=2015-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759536, encodeId=c71f1e59536db, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Jan 24 20:42:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637067, encodeId=502c163e06752, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jun 22 01:42:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27076, encodeId=4a812e076e4, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:38:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22752, encodeId=753a22e5279, content=有意思！, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Wed May 06 14:35:00 CST 2015, time=2015-05-06, status=1, ipAttribution=)]
    2016-01-24 ms5439512287675881

    #BET#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1901276, encodeId=cbf119012e6ed, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Oct 13 20:42:00 CST 2015, time=2015-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759536, encodeId=c71f1e59536db, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Jan 24 20:42:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637067, encodeId=502c163e06752, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jun 22 01:42:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27076, encodeId=4a812e076e4, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:38:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22752, encodeId=753a22e5279, content=有意思！, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Wed May 06 14:35:00 CST 2015, time=2015-05-06, status=1, ipAttribution=)]
    2015-06-22 ms9608593228839890

    #DIA#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1901276, encodeId=cbf119012e6ed, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Oct 13 20:42:00 CST 2015, time=2015-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759536, encodeId=c71f1e59536db, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Jan 24 20:42:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637067, encodeId=502c163e06752, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jun 22 01:42:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27076, encodeId=4a812e076e4, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:38:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22752, encodeId=753a22e5279, content=有意思！, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Wed May 06 14:35:00 CST 2015, time=2015-05-06, status=1, ipAttribution=)]
    2015-06-11 ljjj1053

    好好学习一下

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1901276, encodeId=cbf119012e6ed, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Oct 13 20:42:00 CST 2015, time=2015-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759536, encodeId=c71f1e59536db, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Jan 24 20:42:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637067, encodeId=502c163e06752, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jun 22 01:42:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27076, encodeId=4a812e076e4, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:38:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22752, encodeId=753a22e5279, content=有意思！, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Wed May 06 14:35:00 CST 2015, time=2015-05-06, status=1, ipAttribution=)]
    2015-05-06 qingfengqishi5

    有意思！

    0

相关资讯

Nat Med：同期两项糖尿病重要成果

最近，加拿大多伦多综合医院研究所的研究人员发现，二甲双胍（最广泛使用的2型糖尿病治疗药物）和白藜芦醇——在红葡萄酒中发现的一种化合物，可触发小肠中的新信号转导通路，从而降低血糖。该研究结果以两篇论文的形式发布在四月六日同期出版的《Nature Medicine》杂志。该研究小组由Tony Lam博士和他的同事Frank Duca带领，包括研究生Clemence Cote和Brittany Rasm

Lancet：阿格列汀不增加2型糖尿病心衰风险（EXAMINE 试验）

先前有一项EXAMINE研究证明DPP-4抑制剂阿格列汀与安慰剂相比，在增加T2DM主要心血管事件风险中呈非劣性。而另一项报道称使用DPP-4抑制剂可能增加住院患者心衰风险，令人担忧。因此，近来有研究进行另一项EXAMINE评估阿格列汀对入院患者发生心衰的影响。 试验中，研究者将已接受糖尿病标准化和心血管疾病预防治疗的2型糖尿病合并ACS患者，随机分为阿格列汀或安慰剂治疗组。 预先设定的评价终

JAMA：家族性高胆固醇血症与2型糖尿病的患病率之间的关联

家族性高胆固醇血症的特征在于外周组织中胆甾醇受损，包括肝和胰腺的受损摄取。与此相反，他汀类药物增加了细胞内胆固醇的吸收，并与2型糖尿病的风险增加有关。我们推测这种跨膜胆固醇运输与2型糖尿病的发展有关。 目的 评价2型糖尿病的患病率和家族性高胆固醇之间的关联。 设计 地点和参与者 1994至2014年间荷兰全国筛查方案所有接受族性高胆固醇血症DNA测试的人（n =63320）。 基于文献或实验

Am J Clin Nutr：多吃鸡蛋可降低患2型糖尿病患病风险？可以！

全世界2型糖尿病的患病率(T2D)不断攀升。鸡蛋成为胆固醇的主要来源,胆固醇水平与血糖升高和2型糖尿病风险增加有关。但是,关于蛋与2型糖尿病的患病风险的研究数据非常有限而且结论具有不一致性。 为了调查蛋与2型糖尿病之间的关系，我们评估了来自芬兰东部的中年男性以及老年男性。本研究收纳了从1984-1989年间2332名42~60岁的男性并基于Kuopio缺血性心脏病危险因素研究（KIHD）并记录基

Diabetologia：妊娠期糖尿病孕妈妈要小心！

妊娠期间的糖尿病有两种情况，一种为妊娠前已确诊糖尿病，称“糖尿病合并妊娠”；另一种为妊娠前糖代谢正常或有潜在糖耐量减退、妊娠期才出现或确诊的糖尿病，称为“妊娠期糖尿病（GDM）”。妊娠期糖尿病（GDM）孕妇糖代谢多数于产后能恢复正常，但将来患2型糖尿病机会增加。

才子佳人！GSK携手冷泉港向肥胖和二型糖尿病发起冲锋

最近，美国生物医药研究重镇冷泉港实验室宣布将与英国生物医药巨头葛兰素史克公司建立长期合作。双方将在肥胖和二型糖尿病新疗法的研究开发方面进行合作研究。 协议规定，冷泉港实验室和葛兰素史克公司的研究人员将围绕PTP1B这种蛋白酪氨酸磷酸化酶进行研究。PTP1B被认为在机体产生胰岛素抵抗和瘦素抵抗中起到重要作用，这些早已成为困扰肥胖症和糖尿病治疗领域多时的难题。 数据显示，2011年全世界共